Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives

A method of inhibiting the activity of glycogen synthase kinase 3-beta (GSK3-β), which comprises administering to a patient in need of said inhibition a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein:
• X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom;
• Y represents a bond, a carbonyl group, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group;
• R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the rings being optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group or a halogen atom;
• R2 represents a benzene ring or a naphthalene ring;
• the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a methylenedioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro, a cyano, an amino, a C1-5 monoalkylamino group or a C2-10 dialkylamino group;
• R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom;
• R4 represents a hydrogen atom, a C1-4 alkoxy carbonyl group, a C3-6 cycloalkyl carbonyl group, a benzoyl group, a C1-6 alkyl group, the groups being optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group or a C1-4 alkoxy group;
• o and m represent 1 to 2;
• n represents 0 to 3;
• p represents 0 to 2;
• and
• q represents 0 to 2.